Trial Profile

A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions

Most Recent Events

05 Feb 2025 Planned End Date changed from 1 Jan 2029 to 1 Jan 2027.
21 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jan 2029.
17 Jun 2022 Updated results (as of 14 Feb 2022) reporting long-term safety and efficacy with median follow-up now of over 41 months presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com